These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751 [TBL] [Abstract][Full Text] [Related]
5. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
6. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. Smith RJ; Hiatt WR JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296 [No Abstract] [Full Text] [Related]
8. Substituting for cerivastatin (Baycol). Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579 [No Abstract] [Full Text] [Related]
9. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. McAdams M; Staffa J; Dal Pan G Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291 [TBL] [Abstract][Full Text] [Related]
11. Weighing the benefits of high-dose simvastatin against the risk of myopathy. Egan A; Colman E N Engl J Med; 2011 Jul; 365(4):285-7. PubMed ID: 21675881 [No Abstract] [Full Text] [Related]
12. [Massive rhabdomyolysis associated with the use of cerivastatin monotherapy]. Vera M; Pou M; Botey A; Cases A Nefrologia; 2001; 21(6):613-4. PubMed ID: 11881437 [No Abstract] [Full Text] [Related]
13. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. Schmidt GA; Hoehns JD; Purcell JL; Friedman RL; Elhawi Y J Am Board Fam Med; 2007; 20(4):411-6. PubMed ID: 17615423 [TBL] [Abstract][Full Text] [Related]
19. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'. Eriksson M; Angelin B; Sjöberg S J Intern Med; 2005 Mar; 257(3):313-4. PubMed ID: 15715689 [No Abstract] [Full Text] [Related]
20. FDA panel vetoes OTC version of cholesterol drug. Walczak IM Diabetes Technol Ther; 2000; 2(3):484. PubMed ID: 11467353 [No Abstract] [Full Text] [Related] [Next] [New Search]